In one paragraphArticle in Genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
María Lourdes Garza-RodríguezServicio de Oncología, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey 66451, Nuevo Leon, Mexico.
Eren Adrián Alejandro Vargas-MárquezServicio de Oncología, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey 66451, Nuevo Leon, Mexico.ORCID 0009-0001-2572-7076 Dione AguilarBreast Cancer Center, Hospital Zambrano Hellion TecSalud, San Pedro Garza Garcia 66260, Nuevo Leon, Mexico.
Samantha Trujillo-BorniosServicio de Oncología, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey 66451, Nuevo Leon, Mexico.
Hugo Leonid Gallardo-BlancoServicio de Oncología, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey 66451, Nuevo Leon, Mexico.ORCID 0000-0002-7816-4967 Oscar Vidal-GutiérrezServicio de Oncología, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey 66451, Nuevo Leon, Mexico.
Diana Cristina Pérez-IbaveServicio de Oncología, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey 66451, Nuevo Leon, Mexico.
Carlos Horacio Burciaga-FloresServicio de Oncología, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey 66451, Nuevo Leon, Mexico.ORCID 0000-0002-7723-8354 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Cyclin-Dependent Kinase Inhibitor p16Founder EffectAdultAgedBreast NeoplasmsFemaleGenetic Predisposition to DiseaseGerm-Line MutationHumansMaleMelanomaMexicoMiddle AgedPedigreePhenotypeCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16breast cancerCDKN2Afounder effectgermline varianthereditary cancer
Identifiers
PMID42194989
PMCPMC13206291
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390